Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine safety and the maximum tolerated dose (MTD) of
GRN163L and Velcade with and without Decadron when administered to patients with refractory
or relapsed multiple myeloma.